May 11, 2023 4:05 pm EDT Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
May 8, 2023 8:00 am EDT Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
Mar 30, 2023 4:05 pm EDT Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Mar 23, 2023 8:00 am EDT Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Feb 28, 2023 4:05 pm EST Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
Feb 15, 2023 9:51 am EST Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
Jan 12, 2023 8:00 am EST Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops